IRLAB Therapeutics Logo

IRLAB Therapeutics

Developing novel drugs for Parkinson's disease and other neurodegenerative CNS disorders.

IRLAB | ST

Overview

Corporate Details

ISIN(s):
SE0012675361 (+1 more)
LEI:
549300JAT34LHEI0DH60
Country:
Sweden
Address:
Arvid Wallgrens backe 20, 413 46 Göteborg
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

IRLAB Therapeutics is a drug discovery and development company specializing in novel treatments for neurodegenerative conditions, with a primary focus on Parkinson's disease and other Central Nervous System (CNS) disorders. The company's pipeline is generated by its proprietary research platform, the Integrative Screening Process (ISP), a systems pharmacology discovery method built on an extensive, unique database of CNS compounds. Key clinical-phase candidates include mesdopetam (IRL790), developed to treat levodopa-induced dyskinesia (LIDs), and pirepemat (IRL752), aimed at addressing impaired balance and falls associated with Parkinson's disease.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-29 07:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i IRLAB Therapeutics AB
Swedish 47.7 KB
2025-08-29 07:00
Declaration of Voting Results & Voting Rights Announcements
Change in number of shares and votes in IRLAB Therapeutics AB
English 47.0 KB
2025-08-27 07:00
Interim Report
Swedish 377.6 KB
2025-08-27 07:00
Interim Report
English 373.0 KB
2025-08-21 11:00
Board/Management Information
IRLAB appoints Roy Jonebrant as interim CFO
English 38.2 KB
2025-08-21 11:00
Board/Management Information
IRLAB utser Roy Jonebrant till tillförordnad CFO
Swedish 38.8 KB
2025-08-11 09:00
Board/Management Information
IRLAB's CFO Viktor Siewertz leaves the company for a new leading position
English 39.6 KB
2025-08-11 09:00
Board/Management Information
IRLAB:s CFO Viktor Siewertz lämnar bolaget för ny ledande position
Swedish 40.0 KB
2025-07-18 18:31
Share Issue/Capital Change
IRLAB announces the outcome of the company’s rights issue
English 64.4 KB
2025-07-18 18:31
Share Issue/Capital Change
IRLAB offentliggör utfall i bolagets företrädesemission
Swedish 64.4 KB
2025-07-14 07:00
Share Issue/Capital Change
Sista dag för handel med teckningsrätter i IRLAB:s företrädesemission
Swedish 55.9 KB
2025-07-14 07:00
Share Issue/Capital Change
Last day of trading in subscription rights in IRLAB’s rights issue
English 56.0 KB
2025-07-03 07:00
Share Issue/Capital Change
The subscription period in IRLABS’s rights issue of shares commence today
English 57.2 KB
2025-07-03 07:00
Share Issue/Capital Change
Idag inleds teckningsperioden i IRLAB:s företrädesemission av aktier
Swedish 57.4 KB
2025-07-02 15:00
Prospectus
IRLAB offentliggör informationsdokument i samband med företrädesemissionen
Swedish 56.0 KB

Automate Your Workflow. Get a real-time feed of all IRLAB Therapeutics filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for IRLAB Therapeutics via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-05 Kristina Torfgård Other Buy 9,000 140,850.00 SEK
2024-08-05 Kristina Torfgård Other Buy 4,500 70,875.00 SEK
2024-05-14 Gunnar Olof Olsson Other Buy 2,000 31,000.00 SEK
2024-05-10 Daniel Johnsson Other Buy 20,000 259,680.00 SEK
2023-04-03 Joakim Tedroff Other Buy 51,430 2,038,685.20 SEK
2022-09-01 Richard Godfrey Other Buy 5,000 174,457.00 SEK
2022-08-30 Viktor Siewertz Other Buy 40 1,420.00 SEK
2022-08-29 Viktor Siewertz Other Sell 40 1,408.00 SEK
2022-07-15 Joakim Tedroff Other Other 84,148 N/A
2022-05-31 Viktor Siewertz Other Buy 4,500 170,370.00 SEK

Peer Companies

Company Country Ticker View
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea 291650
Arctic Bioscience Logo
Develops pharma & nutra ingredients from marine lipids for autoimmune & wellness applications.
Norway ABS
ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway AZT
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands 1AE
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden AROC
Ascelia Pharma Logo
Develops novel drugs for rare oncology, including an oral MRI contrast agent for cancer patients.
Sweden ACE
Specializes in hormone drugs for OB/GYN, urology, internal medicine, and animal health.
Japan 4886
Astellas Pharma Inc. Logo
A global pharmaceutical company developing innovative medicines for unmet needs, focusing on oncology.
Japan 4503

Talk to a Data Expert

Have a question? We'll get back to you promptly.